Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Natural anti-inflammatory

This article was originally published in The Tan Sheet

Executive Summary

RejuveNature is positioning its InflaMend product as a natural alternative to non-steroidal anti-inflammatory drugs for pain relief from conditions such as arthritis, post-exercise joint pain and inflammation, according to a June 13 release. The product capsules contain celery seed and ginger root extracts as well as green tea and turmeric among other ingredients to "help address the swelling and discomfort of inflammation." The firm also cites a recent British Medical Journal meta-analysis that linked the NSAID class with increased vascular events (1"The Tan Sheet" June 5, 2006, p. 5). "Unlike the ingredients in NSAIDs and drugs like [Merck's] Vioxx, the...ingredients in InflaMend don't completely block [inflammatory] enzymes, but reduce inflammation while allowing normal healing to occur," the company explains...

You may also be interested in...



High-Dose Ibuprofen, COX-2s Show Similar Vascular Event Risk – Study

A meta-analysis of NSAID trials supports the hypothesis that increased risk of vascular events is a "class effect" of all NSAID types, including traditional NSAID forms like ibuprofen and diclofenac

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel